Biocon Biologics Ltd (BBL) has reached significant achievement with Health Canada's approval of Yesintek (ustekinumab injection) and Yesintek IV, which are biosimilars of Stelara and Stelara IV. The Notice of Compliance was issued on...
Johnson & Johnson announced impressive outcomes for a subcutaneous formulation of amivantamab (Rybrevant) which achieved a 45% overall response rate (ORR) in individuals with advanced head and neck squamous cell carcinoma (HNSCC)...
Novartis announced that Cosentyx met its primary endpoint and all secondary endpoints in the Phase III REPLENISH study, a significant milestone in the treatment of polymyalgia rheumatica. At Week 52, Cosentyx demonstrated statistically...
Pfizer Inc. publicly released updated outcomes from the Phase 2 PHAROS trial examining Braftovi (encorafenib) + Mektovi (binimetinib) in adult subjects with metastatic non-small cell lung cancer (mNSCLC) harboring the BRAF V600E mutation...
Eli Lilly and Company has announced strong Phase 3 data for its investigational oral GLP-1 therapy Orforglipron from ACHIEVE-2 and ACHIEVE-5 trials, which could potentially lay the groundwork for a new treatment standard in type 2 diabetes...
On Monday AbbVie proclaimed that its newest arthritis medication, Rinvoq, outperformed the company’s established best-selling product Humira in a head-to-head clinical study. These findings represent a substantial achievement for AbbVie as it...
Novo Nordisk has made a significant advance in the rare disease sector by signing a definitive asset purchase and license agreement with Omeros Corporation to acquire its clinical-stage MASP-3 inhibitor zaltenibart...
.jpeg){kind=spacer}
CDSCO has given approval to Reliance Life Sciences Pvt. Ltd. for conducting a Phase I/III clinical trial of its biosimilar Nivolumab (R-TPR-067, RLS-Nivolumab). The approval is subsequent to the Subject Expert Committee (Oncology).
.png)
Roche announced it will present over 30 abstracts on more than 10 different types of cancer at the European Society for Medical Oncology (ESMO) Congress 2025, highlighting its commitment to progressing cancer care.
In a significant public health milestone, the World Health Organization (WHO) has recognized the Maldives for successfully eliminating mother-to-child transmission (EMTCT) of hepatitis B, while also upholding its previous validation (in 2019) for EMT
.jpg)
, CDSCO.jpg)